PALVELLA THERAPEUTICS, INC. Annual Report Summary

I’ve put together this guide to help you understand Palvella Therapeutics’ performance this past year. My goal is to explain their progress and financial health clearly, without the confusing financial jargon.

1. What does this company do?

Palvella is a drug developer focused on rare genetic skin diseases and vascular malformations. They are currently in the research phase, running clinical trials to prove their treatments work. Their lead product is QTORIN (rapamycin) anhydrous gel. It aims to treat conditions like Pachyonychia Congenita, Gorlin Syndrome, and venous malformations—none of which currently have FDA-approved drug treatments.

2. A Big Change: The Merger

The biggest news this year is a major transformation. In December 2024, the company (formerly Pieris Pharmaceuticals) completed a merger with "Legacy Palvella." They rebranded as Palvella Therapeutics and shifted their entire focus to skin-disease treatments. Because of this, the company’s current operations are entirely centered on the QTORIN platform.

3. Financial Health

Palvella is in a phase where they spend heavily to develop products. They have $0 in product sales because they have no approved products yet. They expect to lose money for the foreseeable future while they run clinical trials.

• Cash and Value: As of June 30, 2025, the company had about $27.4 million in cash. At that time, the company was worth about $196.7 million on the stock market.
• The Reality: The company is spending cash quickly to fund Phase 2 and Phase 3 trials. They have stated that their current cash will not last until their programs are finished. They will need to raise more money by selling more shares or taking on debt. For you, this likely means more shares will be issued, which reduces your ownership percentage in the company.

4. Major Wins and Challenges

• The Wins: The merger gave the company a public listing and a simpler structure. They also hold "Orphan Drug Designation" for QTORIN. This provides benefits like tax credits and potential market exclusivity for seven years if the drug is approved.
• The Challenges: They are in a high-stakes race against time. Because they have no other products, their entire value depends on the success of QTORIN. If clinical trials fail or the FDA denies approval, the company has no other products to fall back on.

5. Key Risks

The biggest risk is that the drug might fail in clinical trials or fail to win FDA approval. Additionally, the company faces a "liquidity risk." Since they have no income, they depend entirely on outside investors. If the market turns sour, they may be unable to raise the money needed to finish their trials, which could force them to stop research or sell the company.

6. Future Outlook

The company is focused on hitting key clinical milestones for QTORIN. Their future depends on passing FDA requirements and eventually launching the product. This is a high-risk, high-reward situation. Expect the stock price to remain volatile and react sharply to any news about trial results or fundraising.

Investor Takeaway: Palvella is essentially a "bet" on the success of a single drug platform. Before investing, ask yourself if you are comfortable with a company that has no current revenue and will likely need to ask shareholders for more money in the near future to keep its clinical trials running. If you are looking for stability, this is likely not the right fit; if you are looking for high-upside potential in the rare disease space, this is a company to watch closely for upcoming clinical trial data.